Kate Elder and Jennifer Cohn: Vaccines in developing countries: why the high prices?

Global health leaders will gather in Abu Dhabi on 24 and 25 April for a vaccine summit to discuss recent accomplishments and seek ways to expand the impact of childhood vaccination under the decade of vaccines (DoV), an initiative for collective action announced by Bill Gates at the 2010 World Economic Forum. Promoting greater affordability […]

Read More…

Julien Potet and Katy Athersuch: WHO brokered global research and development action plan shelved

Ten years backwards—this was the journey through time that representatives from governments around the world took last week when they gathered at the World Health Organization (WHO) to discuss the recommendations of a 2012 WHO expert group report on how to address the medical research and development (R&D) system’s failures in meeting the needs of […]

Read More…

Grania Brigden: Children with TB—global interest at last

At last, tackling tuberculosis (TB) in children is on the international agenda. This year, for the first time, an estimate of the extent of TB in children was included in the Global Tuberculosis Report. Although the report acknowledged that the figures were approximate and probably too low, their inclusion ends the paucity of global paediatric […]

Read More…

Nathan Ford and Philipp du Cros: Gathering the evidence to improve healthcare in developing countries

A couple of sample dilemmas faced recently in the clinical programmes of the medical humanitarian organisation Médecins Sans Frontières (MSF). “This HIV positive woman in her first trimester of pregnancy is currently on an efavirenz-based regimen, what should we do?” “The patient I just saw in clinic has HIV infection and is hepatitis C antibody […]

Read More…

Leena Menghaney: India’s patent law on trial

This month, two critical legal battles between multinational pharmaceutical companies and the Indian government are taking center stage in an ongoing struggle over India’s medicines patent law. The potential consequences could be dire for governments and people in developing countries that rely on affordable, quality generic medicines produced in India. For example, more than 80% […]

Read More…